Selective JAK inhibitors in development for rheumatoid arthritis.
about
Emerging Therapies for Rheumatoid ArthritisPharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study.Progress toward JAK1-selective inhibitors.Novel treatment options for juvenile idiopathic arthritis.An overview of investigational new drugs for treating ankylosing spondylitis.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.Development of Selective Covalent Janus Kinase 3 Inhibitors.Family-wide Structural Analysis of Human Numb-Associated Protein Kinases.Probiotic bacteria: a viable adjuvant therapy for relieving symptoms of rheumatoid arthritis.Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte.The anti-apoptotic Bcl-2 family protein A1/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK/STAT signaling.Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.Management of primary Sjögren's syndrome: recent developments and new classification criteria.Comprehensive analysis of gene expression and DNA methylation datasets identify valuable biomarkers for rheumatoid arthritis progression.Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects.Identification of 8-Hydroxyquinoline Derivatives Active Against Somatic V658F Mutant JAK1-Dependent Cells.Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment.Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184.Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.Tofacitinib in psoriatic arthritis.The role of the JAK/STAT signal pathway in rheumatoid arthritis.Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritisDesign, synthesis and evaluation of ()-3-(7-(methyl(7-pyrrolo[2,3-]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitorIncreased Binding of Specificity Protein 1 to the Promoter in B Cells Results in Enhanced B Cell Responses in Rheumatoid Arthritis
P2860
Q28078943-3866E3E4-1FF4-49F8-90E9-29F12A4D9F01Q34529981-2C999155-2522-499F-AD0A-A31D9F28DADAQ34533371-45D4EFCC-7517-4480-9EF4-B3546FA86BD8Q34556733-3DDC2E48-C24C-43B5-B404-2F8F5DC3E6BCQ36912333-9DD1FA15-9DE8-41A3-9BC0-5BA62A3A9ADAQ38357083-28C6433E-D167-413F-AD8A-43E5A34BD430Q38570721-5C59E8C1-6B06-4685-A8CA-ED0DBBBA4397Q38631462-A2F1923A-ECD1-4C62-8C00-4F2456CBF972Q38751230-9B9269DF-265B-40C1-9E7E-D46A67FDFCCBQ38759376-6FC195A5-E6EA-4E69-9C2F-F2BCDEF4E240Q38763094-1444BB83-BE41-455E-A2BF-6C8D64049069Q38816598-EEA628D1-CAE2-4277-A76D-B42C8DD32ECDQ38942815-48C45ED9-9EC5-459B-A2BF-32F4752974F6Q39229321-7022A6C7-E30F-483F-96DC-57366CF4E070Q39987891-039586A7-67E6-4397-9D33-3BA532CE71FAQ40169515-F7F6C85B-A252-4908-B23B-09CB1CE8194BQ47266187-BE1EEA9A-9C5D-4089-8D33-32BDF3E0027BQ47602038-B0736500-B14F-459A-9908-6324FBE1ABF3Q47700923-24E4ED16-43EB-47E2-AE48-3CC00DEF4EBCQ49166927-30F44ED1-6FE1-4242-8D51-F8A861C4C115Q50094018-94473DAA-D77B-49E1-BED6-59AE7782E145Q50900106-569BB01A-FCDD-4942-85F8-99F5151474F9Q51318699-BF616417-3E61-404A-AAA5-1930B04FA021Q52624368-3796B872-D3C8-42D8-9BBE-17F8DCD2FFE5Q52642359-82B8D14E-CF35-47D2-BC3F-A7845CA07268Q53232581-EBC4BC0D-1932-4F8A-A5DC-B61B6DE471CBQ54980743-8B71461A-7704-47AC-8B1A-81CA11EABCB1Q54988148-8F2A7C01-86B5-496F-9FFD-2D4FB9D99FD2Q55487787-3644EA5C-63F0-4274-90E7-173E04EFC335Q57330101-744E2326-324A-491E-89B3-5BEC37D057ADQ57557905-E9FE9A63-7FCB-48A3-8440-B18C5EAC9AEEQ58762971-976991C5-D9F7-44FB-BE54-B8214A6570D7
P2860
Selective JAK inhibitors in development for rheumatoid arthritis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Selective JAK inhibitors in development for rheumatoid arthritis.
@ast
Selective JAK inhibitors in development for rheumatoid arthritis.
@en
Selective JAK inhibitors in development for rheumatoid arthritis.
@nl
type
label
Selective JAK inhibitors in development for rheumatoid arthritis.
@ast
Selective JAK inhibitors in development for rheumatoid arthritis.
@en
Selective JAK inhibitors in development for rheumatoid arthritis.
@nl
prefLabel
Selective JAK inhibitors in development for rheumatoid arthritis.
@ast
Selective JAK inhibitors in development for rheumatoid arthritis.
@en
Selective JAK inhibitors in development for rheumatoid arthritis.
@nl
P2860
P1476
Selective JAK inhibitors in development for rheumatoid arthritis.
@en
P2093
Peter Norman
P2860
P304
P356
10.1517/13543784.2014.918604
P407
P577
2014-05-12T00:00:00Z